IRB #

STUDY00023293

Title

An Open-Label, Randomized, Phase 2, Umbrella Study of Various Neoadjuvant Therapies for Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy And Undergoing Radical Cystectomy (Optimus)

Principal Investigator

Jacqueline Vuky

Study Purpose

The purpose of this study is to examine various treatments (either monotherapy or combination therapy) given in the neoadjuvant setting before radical cystectomy

Medical Condition(s)

Bladder cancer

Eligibility Criteria

Confirmed transitional cell urothelial carcinoma

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

Approximately 6 months

Minors Included

No

Contact

Knight Clinical Trials
503-494-1080
trials@ohsu.edu

Sponsor

Incyte Corporation

Recruitment End

06/01/2023

Compensation Provided

No


Go Back